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Endometrial stromal sarcomas (ESSs) belong to the rarest uterine malignancies (prevalence category <1-9/1,000,000).
According to the new 2014 World Health Organisation (WHO) classification, they are separated into four categories;
benign endometrial stromal nodules (ESNs), low grade endometrial stromal sarcomas (LG-ESSs), high-grade
endometrial stromal sarcomas (HG-ESSs) and undifferentiated uterine sarcomas (UUSs). Due to heterogeneous
histopathologic appearance these tumors still represent diagnostic challenge, even for experienced pathologists. ESSs
are genetically very heterogeneous and several chromosomal translocations and gene fusions have so far been
identified in these malignancies. To date the JAZF1/SUZ12 gene fusion is by far the most frequent and seems to be the
cytogenetic hallmark of ESN and LG-ESS. Based on present literature data this gene fusion is present in approximately
75 % of ESN, 50 % of LG-ESS and 15 % of HG-ESS cases. The frequency of JAZF1/SUZ12 appearance varies between
classic ESS and different morphologic variants. This gene fusion is suggested to become a specific diagnostic tool,
especially in difficult borderline cases. In combination with the recently described YWHAE/FAM22 gene fusion the
JAZF1/SUZ12 fusion could be used to differentiate between LG-ESS and HG-ESS. The purpose of this review is to
summarize literature data published in last two and a half decades about this gene fusion, as a contribution to our
understanding of ESS genetics and pathogenesis.
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Background
The pattern of different genetic rearrangements de-
scribed in endometrial stromal sarcomas (ESSs) seems
to be non-random. The chromosome arms 6p and 7p
are frequently involved. One of the most common gen-
etic alterations described in ESSs is the t(7;17)(p15;q21)
chromosomal translocation. In some early studies this
chromosomal change was described as a specific, non-
random chromosome abnormality associated with low-
grade endometrial stromal sarcomas (LG-ESSs) [1]. The
first description of a recurrent chromosomal transloca-
tion was t(7;17)(p15;q21) in 1991 by Sreekantaiah et al.,
in a 58 years old women with metastatic LG-ESS [2]. At
the chromosome breakpoints sites 7p15 and 17q21,
fusion of two zinc-finger proteins was described; the so-
called JAZF1/JJAZ1 gene fusion [3]. Based on their
structural features, these genes were given the acronyms
JAZF1, for Juxtaposed with Another Zinc Finger gene,
and JJAZ1, for Joined to JAZF1 (lately named and re-
ferred in this review as SUZ12 - suppressor of zeste-12
protein). This chromosomal translocation results in a
chimeric RNA in which 5′ end (the first three exons
from five in total) of the JAZF1 gene on chromosome 7
is fused with the 3′ end (the last 15 exons from 16 in
total) of the SUZ12 gene on chromosome 17. During
the past two and a half decades the classification of
ESSs was modified several times, the most recent in
2014 [4, 5]. Thus, the JAZF1/SUZ12 gene fusion should
be revised with respect to the newest nomenclature.
Detection methods
The most frequently used method for detection of
JAZF1/SUZ12 (formerly JAZF1/JJAZ1) gene fusion is
reverse-transcriptase polymerase chain reaction (RT-
PCR). However, one serious pitfall in detecting this gene
fusion by RT-PCR is the preservation of the material
used for RNA isolation. The cryo-preserved tissue is
more suitable for isolation of high-quality RNA than
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formalin-fixed, paraffin-embedded (FFPE) tissue. The
RT-PCR reaction in samples with poor-quality RNA may
deliver false negative results. Huang et al. described four
of ten frozen samples and only one of five FFPE ESS
samples to be positive for JAZF1/SUZ12 fusion tran-
scripts [6]. In our study from 2005 we analysed 22 endo-
metrial stromal tumors (ESTs); 20 LG-ESSs and 2
undifferentiated endometrial sarcomas (UESs) [7]. Out
of 20 LG-ESSs, 16 (80 %) were positive for JAZF1/
SUZ12 gene fusion. We also compared PCR results per-
formed with RNA isolated from both, cryo-preserved
and FFPE tissue samples from three patients. Whereas
the cryo-preserved material of two ESS cases was posi-
tive for JAZF1/SUZ12 gene fusion, these cases were
negative in their FFPE counterparts. Therefore we opti-
mized an RT-PCR reaction for final PCR-product size of
93 bases of the JAZF1/SUZ12 gene fusion sequence. Ac-
cordingly, two false-negative FFPE cases showed positive
amplification of the specific JAZF1/SUZ12 fusion se-
quence, which was confirmed by direct sequencing of
the PCR product [7].
Nucci et al. were able to analyse only 16 of 24 LG-
ESSs cases due to inadequate tissue quality and/or failed
isolation of high-quality DNA [8]. Kurihara et al. col-
lected 31 ESS cases, but could only analyse the JAZF1/
SUZ12 gene fusion in 18 of them, describing the rest as
“noninformative” [9]. This was because the expression
level of the reference gene (GAPDH) was lower than the
cut-off level and suggests most probably the inadequate
quality of the RNA from the FFPE material. The sum-
mary of the data published so far indicates that only
approx. 75 % of all EST cases can be assessed for JAZF1/
SUZ12 fusion transcripts (Table 1, column “informative
for JAZF1/SUZ12”).
In addition to RT-PCR, the interphase fluorescence in
situ hybridisation (FISH) seems to be the method of
choice for detection of the JAZF1/SUZ12 fusion. The
optimisation of the interphase FISH-based detection of
JAZF1/SUZ12 gene fusion in archival FFPE material was
described by Oliva et al. [10]. The application of this
method is of great importance because the majority of
archival material is available in this form, whereas cryo-
preserved tissue is rare. However, some potential pitfalls
of the FISH analysis must be taken into account: i) false
monosomy/polysomy can occur due to sectioning arti-
facts, ii) the FISH technology is quite time-consuming
and labor-intensive. In order to exclude false-negative
results on archival FFPE tissue samples, further opti-
misation of accurate RT-PCR method and the combin-
ation of both methods, RT-PCR and FISH, is highly
recommended.
Frequency in different EST variants
Studies concerning the JAZF1/SUZ12 gene fusion in
different ESS variants are rare. Based on histological
appearance, the accurate comparison of different vari-
ants of all described ESS cases is challenging because;
(i) criteria for histological classification based on
morphology varied in different studies and institu-
tions, and/or they were not precisely specified, (ii) the
number of cases in different categories was usually
too small to make a precise conclusion on the fre-
quency of JAZF1/SUZ12 fusion in ESSs of different
histologic subtypes.
Table 1 Incidence of JAZF1/SUZ12 fusion transcript in uterine ESTs












Koontz (2001) [3] 3/3 (100) 5/5 (100) 3/7 (43) 0/10 (0) 15 15 (100)
Micci (2003) [18] - 1/4 (25) - - 4 4 (100)
Huang (2004) [6] 2/2 (100) 3/13 (23) - - 15 15 (100)
Hrzenjak (2005) [7] - 16/20 (80) 0/2 (0) 0/10 (0) 22 22 (100)
Micci (2006) [36] - 0/3 (0) - - 3 3 (100)
Oliva (2007) [10] 3/6 (50) 0/1 (0) - - 10 6 (60)
Nucci (2007) [8] 4/4 (100) 8/16 (50) - - 32 20 (63)
Kurihara (2008, 2010) [9,
12]
4/6 (67) 5/11 (45) 1/6 (17) - 37 23 (62)
Li (2007) [33] 4/4 (100) - - - 4 4 (100)
D'Angelo (2013) [37] 1/3 (33) 1/13 (8) 0/7 (0) - 23 22 (96)
Isphording (2013) [45] - 7/16 (44) 0/6 (0) - 22 22 (100)
Total (%) 21/28 (75) 46/102 (45) 4/28 (14) 0/20 (0) 187 156 (83)
Abbreviations: ESN endometrial stromal nodule, LG-ESS low-grade endometrial stromal sarcoma, UES undifferentiated endometrial sarcoma, + positive for JAZF1/
SUZ12 gene fusion; total, number of all analyzed samples
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One comparative genomic hybridisation (CGH) study
showed that chromosomal aberrations in ESTs are het-
erogeneous and do not correlate to histologic grades
[11]. Huang et al. described the presence of the JAZF1/
SUZ12 fusion in one case of endometrial stromal nodule
(ESN) with smooth muscle (SM) differentiation [6]. In
their studies Kurihara et al. found the JAZF1/SUZ12
fusion transcript in 4 out of 6 (67 %) ESNs, 5 out of
12 (45 %) LG-ESSs and in 1 out of 3 (33 %) UESs
with nuclear uniformity (UES-U), whereas all three
UES cases with nuclear pleomorphism (UES-P) were
negative [9, 12]. These data for undifferentiated tu-
mors indicate the heterogeneity of this category,
which now according to the 2014 WHO classification
is separated into high-grade endometrial stromal sar-
comas (HG-ESSs) and undifferentiated uterine sarco-
mas (UUSs).
Overall, published data suggest that the JAZF1/SUZ12
fusion is present only in a subset of primary ESTs. These
variations in prevalence might be based on (i) methods
used for tissue collection and/or preservation, (ii) JAZF1/
SUZ12 detection methods (RT-PCR versus FISH), or (iii)
differences between patient populations. In respect to the
ethnic consideration, two studies were published since
now describing clinicopathological features of uterine sar-
comas in South African women [13] and molecular char-
acterisation of a population-based series of ESSs in Kuwait
[14]. In the second study the JAZF1 rearrangement was
reported in 70 % of LG-ESSs, however the presence/ab-
sence of the JAZF1/SUZ12 gene fusion was not clearly
specified. Altogether these data indicate the heterogeneity
of ESS/UES, an issue which can only be solved by analys-
ing larger number of samples.
Data summarizing the incidence of JAZF1/SUZ12 gene
fusion are presented in Table 1. Oliva et al. studied a
subset of 10 ESTs; 9 ESNs and one ESS with smooth
muscle differentiation (SM). Six out of 10 cases were as-
sessable for detection of the JAZF1/SUZ12 fusion and
fusion signals were detected in 3 cases (50 %), both in
endometrial stromal and in SM components [10]. The
authors state that these findings support the idea of a
common origin for endometrial stromal and SM compo-
nents in EST. Furthermore, they suggest this detection
as a supportive method for diagnosis of ESTs with SM
differentiation. This is of high significance because the
distinction between well-differentiated SM neoplasms,
such as cellular leiomyoma, and ESS with predominant
SM differentiation can be challenging even for experi-
enced pathologists.
Huang and co-workers categorized 15 ESSs based on
their histological appearance and showed that the preva-
lence of JAZF1/SUZ12 fusion was mainly limited to the
subset of ESSs with classic histology [6]. Beside these
cases with classic histology, they detected the JAZF1/
SUZ12 fusion in one ESN of mixed SM variant. In our
study we have found 12 out of 14 classic LG-ESSs to be
positive for JAZF1/SUZ12 fusion. Two ESS variants,
which included 1 mixed low-grade ESS with epithelioid
(EP) and sex cord-like differentiation (SC) and 1 with a
fibromyxoid (FM) feature were also positive, whereas the
third ESS with SC differentiation was negative [7]. Both
UUSs analysed in our study were negative for JAZF1/
SUZ12 fusion. This supports the hypothesis, that there
is low, if any, pathologic relationship between LG-ESSs
and undifferentiated uterine sarcomas. We also analyzed
normal endometria (n = 10), leiomyomas (n = 5), leio-
myosarcomas (n = 5), lung carcinomas (n = 3), gastric
carcinomas (n = 3) and hepatic carcinomas (n = 3), all of
which were negative for the JAZF1/SUZ12 fusion
transcript.
In their study with 24 cases of uterine tumors resem-
bling ovarian sex cord tumors (UTROSCT), Staats et al.
used both FISH and RT-PCR to detect the JAZF1/
SUZ12 fusion transcript, but none of 24 UTROSCT
samples were positive [15]. These data indicate that
UTROSCT are not related to ESTs and represent distinct
entity. Kurihara et al. found the JAZF1/SUZ12 fusion
transcript in one of two ESNs with sex SC differentiation
[12]. By using FISH, Nucci et al. detected two ESNs with
smooth muscle differentiation to be positive for the
JAZF1/SUZ12 fusion [8]. The JAZF1/SUZ12 fusion tran-
script was not only found in primary tumors, but also in
metastases and in a primary extrauterine ESS [6].
Kurihara et al. reported about 24 ESTs assayed for
JAZF1/SUZ12 fusion transcript; 6 ESN, 12 ESS and 6
UES cases [9, 12]. Four out of 6 ESNs, six out of 12 ESSs
and one UES-U were positive, whereas all 3 UES-P cases
were negative for JAZF1/SUZ12 gene fusion (Table 2).
These data clearly indicate the heterogeneity of UESs
and can be now, based on WHO 2014 classification dis-
tinguishing between HG-ESS and UUS, observed in a
different context.
Primary extrauterine ESSs are very rare mesenchymal
neoplasms with morphologic features similar to their
uterine counterparts. Sato et al. confirmed the JAZF1/
SUZ12 gene fusion by RT-PCR and FISH analysis in one
primary extrauterine ESS arising from the extraperito-
neal portion of the round ligament in the inguinal canal
[16]. Therefore, they suggested detection of JAZF1/
SUZ12 gene fusion as an additional tool in the diagnosis
of extrauterine ESTs. The JAZF1/SUZ12 fusion tran-
script has been analysed in six additional primary extra-
uterine LG-ESSs. One out of six samples was positive
both by RT-PCR and by FISH, indicating lower preva-
lence of JAZF1/SUZ12 gene fusion in extrauterine in
comparison to uterine ESSs [17]. Few additional extra-
uterine ESSs were analysed sporadically [7, 18, 19] and,
therefore, the significance of this analysis as a diagnostic
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tool for primary extrauterine ESTs is limited by both,
the scarcity and by the low prevalence of these tumors.
Short summary of JAZF1/SUZ12 gene transcript dis-
tribution in different histologic subtypes of ESTs is
shown in Table 2. Albeit, this summary should be taken
with caution as molecular diagnostic testing of ESTs for
JAZF1/SUZ12 gene fusion is still not a standard and
histological classification of described ESTs is frequently
not complete. Furthermore, different detection methods
were used in different studies, which might have an in-
fluence on the final results. Altogether, these data sug-
gest that JAZF1/SUZ12 fusion is frequently but not
consistently present in ESNs and in ESTs of classic hist-
ology and less often in other histological subtypes. These
data support the idea about genetic heterogeneity be-
tween ESTs with different histology and might have an
important implication on the diagnosis of different EST
subtypes.
Fusion protein - Putative biological functions
The ESTs exhibit different patterns of genetic aberra-
tions, but rearrangements of the chromosomes 6, 7 and
17 seem to be the most common. At the 7p15 and
17q21 breakpoints genes named JAZF1 and SUZ12
(formerly JJAZ1) were identified. It has been shown that
they are associated with the t(7;17)(p15;q21) alteration
in ESSs [3]. In cDNA sequences from both genes there
are so-called zing finger motifs, which are characteristic
for DNA-binding proteins [20, 21]. In our previous
study, we showed that the breakpoint in the JAZF1/
SUZ12 fusion sequence, detected by direct sequencing
of positive PCR-products, was the same in all 16 positive
cases [7]. In this break-point G-435 from the JAZF1
sequence was followed by A-468 from the SUZ12
sequence and was, therefore, identical with the break-
point described by other authors in a limited number of
cases [3, 6, 18]. These findings indicate that the break-
point in the fusion gene sequence is highly conserved.
As shown by Northern blot hybridization and RNase
protection assay, the cDNAs for JAZF1 and SUZ12 rep-
resent transcripts for predicted proteins composed of
243 and 739 amino acids, respectively [3]. Tumor-
specific mRNA transcript for predicted protein contains
5-prime end of the JAZF1 and 3-prime end of the
SUZ12 sequence, with retaining zinc finger motifs from
both genes. Two zinc finger domains in JAZF1 gene
show homology to the yeast protein Sfp1p, which nega-
tively regulates the G2/M transition in Streptomyces cer-
evisiae by transcriptional activation of some other genes
like PDS1 and Esp1p [3]. Based on this, the authors sug-
gested that the JAZF1/SUZ12 chimeric protein might
disrupt transcription in lineage-specific manner. The loss
of expression of a normal JAZF1 has been shown in
some ESS cases [3]. Additionally, a growing body of evi-
dence is showing that the loss of expression for normal
version of the JAZF1 in various malignancies, thus sug-
gesting that the JAZF1 may have a role as a tumor sup-
pressor gene [22]. Though, the specific function of the
JAZF1 and SUZ12 genes in human malignant cells is still
not known.
Using JJAZ1-specific antibody, Li et al. showed for the
first time that JAZF1/SUZ12 RNA is translated into the
fusion protein in immortalized, normal human endomet-
rial stromal cells (HESC) [23]. However, these findings
Table 2 Distribution of JAZF1/SUZ12 fusion transcript in different histological subtypes of ESTs
ESN, total (+) ESS, total (+) UES, total (+)
Ref. Classic SM Mixed Classic SM EP FM SC Mixed UES-U UES-P
[3] 3a (3) 5a (5)
[6] 1 (1) 1 (1) - 3 (3) 2 (0) 2 (0) 2 (0) - - - -
[7] - - - 16 (14) - - 1 (1) 1 (0) 1 (1) - 2 (0)
[8] 2 (2) 2 (2) 16 (8)
[9], [12] 6 (4) - - 11 (5) - - - 1 (0) - 3 (1) 3 (0)
[10] 5 (2) - - 1 (1) - - - - - - -
[35] 2 (1) - 1 (0) 5 (1) 1 (0) - - 4 (0) 3 (0) 3 (0) 4 (0)
[44] - - - 16a (7) - - - - - 6a (0) -
Total Nr. 19 (13) 3 (3) 1 (0) 73 (44) 3 (0) 2 (0) 3 (1) 6 (0) 4 (1) 12 (1) 9 (0)
+ / total (n = 135) 9.6 % 2.2 % - 32.6 % - - 0.7 % - 0.7 % 0.7 % -
+ / type 69.6 % 50.5 % 4.8
+ / subtype 68 % 100 % - 60 % - - 33 % - 25 % 8 % -
Abbreviations: Ref references, ESN endometrial stromal nodule, LG-ESS low-grade endometrial stromal sarcoma, UES undifferentiated endometrial sarcoma; classic,
with classic histology, SM with smooth muscle differentiation, EP with epithelioid features, FM with fibromyxoid features, SC with sex cord-like differentiation, U
with nuclear uniformity, P with nuclear pleomorphism
a,morphologic subtype was not precisely described in original paper; +, positive for JAZF1/SUZ12 fusion transcript; total, number of samples suitable for analyses
(cases described in original paper as “non informative” or “not analyzed” were excluded from calculations)
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are not consistent with data published latter by Panago-
poulos et al., who did not find this chimeric transcript in
the same cell line. Few possible explanations were dis-
cussed, including different group of examined cells, dif-
ferent culturing conditions and differences in the PCR
approach [24]. Furthermore, it might be that the JAZF1/
SUZ12 fusion RNA in normal endometrial stroma is not
a product of the gene fusion, but rather of some kind of
RNA trans-splicing with unknown mechanisms.
The highest JAZF1 expression level was detected in adult
testis, moderate in placenta, colon, prostate and ovary [25].
Recently, high expression level was detected in liver and
adipose tissue, as well as in induced preadipocytes, suggest-
ing its potential role in lipid metabolism [26, 27]. It has
been shown that JAZF1 encodes a transcriptional corepres-
sor which physically binds to the orphan nuclear receptor
TAK1, which is a regulator of transcription [25]. Interest-
ingly, TAK1 receptor deficient mice are protected against
obesity-linked inflammation, hepatic steatosis, and insulin
resistance [28]. However, its potential role in malignant dis-
eases still remains obscure.
The wild-type JAZF1 protein is expressed in normal
endometrium. Thus, it has been suggested that the
fusion protein might disrupt transcription in a lineage-
specific manner [3]. The JAZF1 shows sequence similar-
ities to the yeast protein Sfp1p, which activates the gene
PDS1 and inhibits the transition from G2 phase to
mitosis in Saccharomyces cerevisiae. However, in trans-
fected human cells the JAZF1 protein does not have any
effect on this transition [3]. Single nuclear polymor-
phisms in the JAZF1 introns have been reported to be
associated with an increases risk of type 2 diabetes [29]
and with increased susceptibility to prostate cancer [30].
The JJAZ1 orthologue gene in Drosophila is mutated
in flies with the SuZ12 phenotype [31]. The SuZ12 pro-
tein is an essential component of the polycomb repres-
sion complex 2 (PRC2), which plays a role in
methylation of lysines 9 and 27 of histone 3. This leads
to chromatin remodelling, increased chromatin com-
pactness and transcriptional gene silencing [32]. Intro-
duction of the JAZF1/SUZ12 expression vector into
cultured HEK-293 (human embryonic kidney) cells sig-
nificantly promoted the proliferation of these cells and
inhibition of apoptosis [33]. This effect was dependent
on suppression of the endogenous SUZ12 and was
present only in cultured cells with silenced endogenous
SUZ12 alleles. In addition, expression levels of EZH2
protein and total trimethyl histone 3 lysine 27 (H3K27),
which are reduced when SUZ12 is deficient in these
cells, were restored to normal levels. Some published
data indicate that SUZ12 is important for stabilization of
the EZH2 protein [34, 35]. Furthermore, the expression
of the JAZF1/SUZ12 protected HEK-293 cells from
serum deprivation and from hypoxia-induced apoptosis.
Based on their results, Li et al. suppose that the SUZ12
might have features of both, an oncogene and a tumor
suppressor gene [33]. Relatively high percentage of posi-
tive ESSs, as well as highly conserved breakpoint in the
fusion gene sequence, suggest that this translocation
might play an important role in ESS/UES pathogenesis.
Since this gene fusion is present also in ESNs, the possi-
bility exists that malignant ESTs can develop from this
benign form. However, the implication of JAZF1/SUZ12
gene fusion for the biology of ESTs is not clarified yet.
Other chromosomal rearrangements in ESSs
Another chromosomal rearrangement has been reported
in the ESSs, containing the JAZF1 gene and the gene se-
quence for so called PHD finger protein 1 (PHF1), lo-
cated at chromosomal band 6p21 [36]. The PHF1 gene
shows high sequence homology to the Drosophila poly-
comblike (PCL) gene and encodes a protein with two
zinc finger motifs. This new JAZF1/PHF1 fusion gene
was first described in two of three analysed ESSs. D'An-
gelo and colleagues described a correlation between the
occurrence of PHF1 rearrangement and ESSs with sex
cord differentiation [37]. In their study all 7 cases with
sex cord differentiation were positive for PHF1 re-
arrangement, whereas only one was positive for JAZF1
rearrangement. One recent study, with a total of 40
cases, showed that 36 % of LG-ESSs (8 of 22) and none
of 17 UESs (10 with nuclear uniformity and 7 with nu-
clear pleomorphism) were positive for the JAZF1/PHF1
rearrangement [38].
Panagopoulos et al. described an endometrial sarcoma
cell line, the JHU-ESS1, containing the JAZF1/PHF1
gene fusion [39]. They confirmed by direct sequencing
that exon 3 of JAZF1 (nucleotide 626) was fused with
exon 2 of PHF1 (nucleotide 276). Thus, this fusion differ
from two chimeras previously described by Micci et al.,
where exon 2 or 3 of JAZF1 was fused with exon 1 or 2
of PHF1, respectively [36]. At the junction in JHU-ESS1
cells, an insertion of 26 nucleotides from intron 3 of
JAZF1 (position 96834–96859) was found, thus main-
taining an open reading frame of the predicted chimeric
transcript. The open reading frame of this fusion con-
sists of 130 amino acids (aa) from JAZF1 and 7 add-
itional aa from an intronic sequence fused with the
proline at position 21 in PHF1. Thus, the putative fusion
protein would contain 684 aa. Micci et al. showed that
the JAZF1/PHF1 fusion sequence has an open reading
frame coding for 657 amino acid residues in one ESS
case and 727 amino acid residues in the second ESS
case. Both putative proteins retain one zinc finger do-
main from JAZF1 and two zinc finger domains from
PHF1 gene and are under control of the JAZF1 promoter
[36]. Although the specific functions of JAZF1 and the
PHF1 and their role in ESS-pathogenesis are not clear,
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one can expect that based on their zinc finger motifs
they are involved in regulation of transcriptional pro-
cesses in tumor cells. Whereas all other gene fusions
from ESTs were detected exclusively in these tumors,
the JAZF1/PHF1 fusion was recently described in the
sarcoma of the heart, thus being the only one detected
outside of the EST spectrum [40].
Recently, a new chromosomal translocation t(10;17)
(q22;p13) was reported in a distinct group of ESS, fusing
two genes: YWHAE, encoding a member of the 14-3-3
family, and either NUTM2A or NUTM2B (formerly re-
ported as FAM22A or FAM22B), respectively [41, 42].
Based on present studies, tumors with YWHAE/NUTM2
rearrangements are associated with high-grade morph-
ology and aggressive clinical behaviour [41, 43–47].
However, they usually do not behave as aggressively as
UUS, the most aggressive form of ESTs. The YWHAE/
NUTM2 and the JAZF1/SUZ12 fusions seem to be mu-
tually exclusive. Therefore, both may be considered as a
support to morphology-based diagnosis, especially in dif-
ficult borderline cases. ESSs with JAZF1 and YWHAE/
NUTM2 rearrangements also differ concerning the es-
trogen- and progesterone-receptor expression, the
YWHAE/NUTM2 tumors being consistently negative
[48]. Although the impact factor of these two fusions on
prognostic and possible therapeutic implications must
be further investigated, these findings already suggest
that application of the hormonal therapy in the
YWHAE/NUTM2 positive ESSs may be less meaningful.
In 2014, Dewaele et al. detected a novel gene fusion
MBTD1-CXorf67 in a subset of LG-ESSs [49]. However,
detection of putative fusion protein and plausible mech-
anistic explanation requires future studies. Two novel
gene fusions, MEAF6/PHF1 and ZC3H7B/BCOR, were
detected in a subset of ESSs with t(1;6)(p34;p21) and
der(22)t(X;22)(p11;q13) genetic alterations, respectively
[50–52]. It is to be expected that a comprehensive gen-
ome and transcriptome analyses, as performed very re-
cently by Choi et al, [53] will help us detecting new
genetic alterations in different EST variants.
Conclusions and future perspectives
ESSs are genetically heterogeneous malignancies, with
following chromosomal translocations identified:
t(7;17)(p15;q21), t(6;7)(p21;p15), t(6;10;10)(p21;q22;p11),
t(1;6)(p34;p21) and t(10;17)(q22;p13). They result in fol-
lowing gene fusions: JAZF1/SUZ12, PHF1/JAZF1, EPC1/
PHF1, MEAF6/PHF1 and YWHAE/FAM22. Data pub-
lished so far show that the JAZF1/SUZ12 fusion is a gen-
etic hallmark of ESNs and of LG-ESSs. Presence of this
fusion in ESNs might suggest that: (i) this genetic alter-
ation is an early event in the tumor development, and
(ii) ESN is a benign precursor of the malignant LG-ESS.
This gene fusion is present in 75 % of ESNs, 45 % of
LG-ESSs and in approx. 14 % of HG-ESSs and the fre-
quency of appearance varies between classic ESS and dif-
ferent morphologic variants. A growing community of
authors suggests that the JAZF1/SUZ12 gene fusion
should become a specific diagnostic tool, especially when
the diagnosis of ESSs is unclear or difficult due to vari-
ous reasons. It might be particularly useful for differen-
tial diagnosis between LG-ESSs and smooth muscle
tumors of the uterus, which are always negative for that
fusion. The fact that JAZF1/SUZ12 gene fusion is only
sporadically positive in HG-ESSs and UUSs support the
hypothesis, that these tumors bear no pathological rela-
tionship with LG-ESSs.
Novel chromosomal translocation (t(10;17)) might also
be useful as a differential diagnostic tool between LG-
ESSs and HG-ESSs. Since the prognosis and the 5-year
survival rate of LG-ESSs and HG-ESSs are drastically
different, the precise distinction between these entities is
clinically very important. Although it is very challenging
to foresee the whole potential benefit behind these new
findings, further investigations in this field will certainly
provide novel insights into our understanding of ESSs
pathogenesis.
Elucidation of the functions of fusion genes/proteins
in uterine sarcomas will further improve our under-
standing of the oncogenic process in these malignancies.
This might lead to the identification of new therapeutic
targets for the treatment of uterine sarcoma.
Abbreviations
BCOR: BCL6 corepressor; CXofr67: chromosome X open reading frame 67;
ESN: endometrial stromal nodule; ESS: endometrial stromal sarcoma; ESS-
EP: endometrial stromal sarcoma with epithelioid differentiation; ESS-
FM: endometrial stromal sarcoma with fibromyxoid feature; ESS-
SC: endometrial stromal sarcoma with sex cord-like differentiation; ESS-
SM: endometrial stromal sarcoma with smooth muscle differentiation;
EST: endometrial stromal tumor; EZH2: enhancer of zeste 2 polycomb
repressive complex 2 subunit; FFPE: formalin-fixed, paraffin-embedded;
FISH: fluorescence in situ hybridisation; HESC: human endometrial stromal
cells; HG-ESS: high-grade endometrial stromal sarcoma; JAZF1: juxtaposed
with Another Zinc Finger gene; JJAZ1: joined to JAZF1; LG-ESS: low-grade
endometrial stromal sarcoma; MBTD1: mbt domain containing 1;
MEAF6: MYST/Esa1-associated factor 6; NUTM2A: NUT family member 2A;
NUTM2B: NUT family member 2B; PCL: polycomblike; PHF1: PHD finger
protein 1; PRC2: polycomb repression complex 2; SUZ12: suppressor of zeste-
12 protein; UES-P: undifferentiated endometrial sarcoma with nuclear
pleomorphism; UES-U: undifferentiated endometrial sarcoma with nuclear
uniformity; UTROSCT: uterine tumor resembling ovarian sex cord tumor;
UUS: undifferentiated uterine sarcoma; YWHAE: tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, epsilon; ZC3H7B: zinc finger
CCCH-type containing 7B.
Competing interests
The author declares that he has no competing interests.
Authors’ contribution
AH made the literature search and wrote the manuscript.
Acknowledgement
This paper is dedicated to the memory of Mrs. Lore Saldow.
Hrzenjak Orphanet Journal of Rare Diseases  (2016) 11:15 Page 6 of 8
Received: 7 January 2016 Accepted: 8 February 2016
References
1. Dal Cin P, Aly MS, De Wever I, Moerman P, Van Den Berghe H. Endometrial
stromal sarcoma t(7;17)(p15-21;q12-21) is a nonrandom chromosome
change. Cancer Genet Cytogenet. 1992;63:43–6.
2. Sreekantaiah C, Li FP, Weidner N, Sandberg AA. An endometrial stromal
sarcoma with clonal cytogenetic abnormalities. Cancer Genet Cytogenet.
1991;55:163–6.
3. Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H, et al.
Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal
tumors. Proc Natl Acad Sci U S A. 2001;98:6348–53.
4. Conklin CM, Longacre TA. Endometrial stromal tumors: The new WHO
classification. Adv Anat Pathol. 2014;21:383–93.
5. Ali RH, Rouzbahman M. Endometrial stromal tumours revisited: and update
base on the 2014 WHO classification. J Clin Pathol. 2015;68:325–32.
6. Huang HY, Ladanyi M, Soslow RA. Molecular detection of JAZF1-JJAZ1 gene
fusion in endometrial stromal neoplasms with classic and variant histology:
evidence for genetic heterogeneity. Am J Surg Pathol. 2004;28:224–32.
7. Hrzenjak A, Moinfar F, Tavassoli FA, Strohmeier B, Kremser ML, Zatloukal K,
et al. JAZF1/JJAZ1 gene fusion in endometrial stromal sarcomas: molecular
analysis by reverse transcriptase-polymerase chain reaction optimized for
paraffin-embedded tissue. J Mol Diagn. 2005;7:388–95.
8. Nucci MR, Harburger D, Koontz JI, Dal Cin P, Sklar J. Molecular analysis of
the JAZF1/JJAZ1 gene fusion by RT-PCR and flurescence in situ
hybridisation in endometrial stromal neoplasms. Am J Surg Pathol. 2007;31:
65–70.
9. Kurihara S, Oda Y, Ohishi Y, Iwasa A, Takahira T, Kaneki E, et al. Endometrial
stromal sarcomas and related high-grade sarcomas: immunohistochemical and
molecular genetic study of 31 cases. Am J Surg Pathol. 2008;32:1228–38.
10. Oliva E, de Leval L, Soslow RA, Herens C. High frequency of JAZF1-JJAZ1
gene fusion in endometrial stromal tumors with smooth muscle
differentiation by interphase FISH detection. Am J Surg Pathol. 2007;31:
1277–84.
11. Halbwedl I, Ullmann R, Kremser ML, Man YG, Isadi-Moud N, Lax S, et al.
Chromosomal alterations in low-grade endometrial stromal sarcoma and
undifferentiated endometrial sarcoma as detected by comparative genomic
hybridization. Gynecol Oncol. 2005;97:582–7.
12. Kurihara S, Oda Y, Ohishi Y, Kaneki E, Kobayashi H, Wake N, et al. Coincident
expression of beta-catenin and cyclin D1 in endometrial stromal tumors
and related high-grade sarcomas. Mod Pathol. 2010;23:225–34.
13. Amant F, Dreyer L, Makin J, Vergote I, Lindeque BG. Uterine sarcomas in
South African black women: a clinicopathologic study with ethnic
considerations. Eur J Gynaecol Oncol. 2001;22:194–200.
14. Ali RH, Al-Safi R, Al-Waheeb S, John B, Al-Ali W, Al-Jassar W, et al. Molecular
characterization of a populatin-based series of endometrial stromal
sarcomas in Kuwait. Human Pathol. 2014;45:2453–62.
15. Staats PN, Garcia JJ, Dias-Santagata DC, Kuhlmann G, Stubbs H, McCluggage
WG, et al. Uterine tumors resembling ovarian Sex cord tumors (UTROSCT)
lack the JAZF1-JJAZ1 translocation frequently seen in endometrial stromal
tumors. Am J Surg Pathol. 2009;33:1206–12.
16. Sato K, Ueda Y, Sugaya J, Ozaki M, Hisaoka M, Katsuda S. Extrauterine
endometrial stromal sarcoma with JAZF1/JJAZ1 fusion confirmed by RT-PCR
and interphase FISH presenting as an inguinal tumor. Virchows Arch. 2007;
450:349–53.
17. Amador-Ortiz C, Roma AA, Huettner PC, Becker N, Pfeifer JD. JAZF1 and
JJAZ1 gene fusion in primary extrauterine endometrial stromal sarcoma.
Hum Pathol. 2011;42:939–46.
18. Micci F, Walter CU, Teixeira MR, Panagopoulos I, Bjerkehagen B, Saeter G, et
al. Cytogenetic and molecular genetic analyses of endometrial stromal
sarcoma: nonrandom involvement of chromosome arms 6p and 7p and
confirmation of JAZF1/JJAZ1 gene fusion in t(7;17). Cancer Genet
Cytogenet. 2003;144:119–24.
19. Tokinaga A, Furuya M, Niino H, Udaka N, Asai-Sato M, Sekido H, et al.
Colonic low-grade endometrial stromal sarcoma and orthotopic
endometrial stromal tumor with limited infiltration sharing the JAZF1-SUZ12
gene fusion. Pathol Int. 2014;64:178–82.
20. Berg JM, Shi Y. The galvanization of biology: a growing appreciation for the
roles of zinc. Science. 1996;271:1081–5.
21. Clarke ND, Berg JM. Zinc fingers in Caenorhabditis elegans: finding families
and probing pathways. Science. 1998;282:2018–22.
22. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial
malignancies. Obstet Gynecol Int. 2010;2010:1–16.
23. Li H, Wang J, Mor G, Sklar J. A neoplastic gene fusion mimics trans-splicing
of TRNAs in normal human cells. Science. 2008;321:1357–61.
24. Panagopoulos I. Absence of the JAZF1/SUZ12 chimeric transcript in the
immortalized non-neoplastic endometrial stromal cell line T HESCs. Oncol
Lett. 2010;1:947–50.
25. Nakajima T, Fujino S, Nakanishi G, Kim YS, Jetten AM. TIP27: a novel
repressor of the nuclear orphan receptor TAK1/TR4. Nucleic Acids Res. 2004;
32:4194–204.
26. Li L, Yang Y, Yang G, Lu C, Yang M, Liu H, et al. The role of JAZF1 on lipid
metabolism and related genes in vitro. Metabolism. 2011;60:523–30.
27. Ming GF, Xiao D, Gong WJ, Liu HX, Liu J, Zhou HH, et al. JAZF1 can regulate
the expression of lipid metabolic genes and inhibit lipid accumulation in
adipocytes. Biochem Biophys Res Commun. 2014;445:673–80.
28. Kang HS, Okamoto K, Kim YS, Takeda Y, Bortner CD, Dang H, et al. Nuclear
orphan receptor TAK1/TR4-deficient mice are protected against obesity-
linked inflammation, hepatic steatosis, and insulin resistance. Diabetes. 2011;
60:177–88.
29. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al.
Clinical risk factors, DNA variants, and the development of type 2 diabetes.
N Engl J Med. 2008;359:2220–32.
30. Prokunina-Olsson L, Fu YP, Tang W, Jacobs KB, Hayes RB, Kraft P, et al.
Refining the prostate cancer genetic association within the JAZF1 gene on
chromosome 7p15.2. Cancer Epidemiol Biomarkers Prev. 2010;19:1349–55.
31. Birve A, Sengupta AK, Beuchle D, Larsson J, Kennison JA, Rasmuson-
Lestander A, et al. Su(z)12, a novel Drosophila Polycomb group gene that is
conserved in vertebrates and plants. Development. 2001;128:3371–9.
32. Müller J, Verrijzer P. Biochemical mechanisms of gene regulation by
polycomb group protein complexes. Curr Opin Genet Dev. 2009;19:150–8.
33. Li H, Ma XY, Wang J, Koontz J, Nucci M, Sklar J. Effects of rearrangement
and allelic exclusion of JJAZ1/SUZ12 on cell proliferation and survival. Proc
Natl Acad Sci U S A. 2007;104:20001–6.
34. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase
activity and the silencing function of the EED-EZH2 complex. Mol Cell. 2004;
15:57–67.
35. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is
essential for mouse development and for EZH2 histone methyltransferase
activity. EMBO J. 2004;23:4061–71.
36. Micci F, Panagopoulos I, Bjerkehagen B, Heim S. Consistent rearrangement of
chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and
EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res. 2006;66:107–12.
37. D'Angelo E, Ali RH, Espinosa I, Lee CH, Huntsman DG, Gilks B, et al.
Endometrial stromal sarcomas with sex cord differentiation are associated
with PHF1 rearrangement. Am J Surg Pathol. 2013;37:514–21.
38. Jakate K, Azimi F, Ali RH, Lee CH, Clarke BA, Rasty G, et al. Endometrial
sarcomas: an immunohistochemical and JAZF1 re-arrangement study in
low-grade and undifferentiated tumors. Mod Pathol. 2013;26:95–105.
39. Panagopoulos I, Mertens F, Griffin CA. An endometrial stromal sarcoma cell
line with the JAFZ1/PHF1 chimera. Cancer Genet Cytogenet. 2008;185:74–7.
40. Schoolmeester JK, Sukov WR, Maleszewski JJ, Bedroske PP, Folpe AL, Hodge
JC. JAZF1 rearrangement in a mesenchymal tumor of nonendometrial
stromal origin - Report of an unusual ossifying sarcoma of the heart
demonstrating JAZF1/PHF1 fusion. Am J Surg Pathol. 2013;37:938–42.
41. Lee CH, Ali RH, Rouzbahman M, Marino-Enriquez A, Zhu M, Guo X, et al.
Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma
with YWHAE-FAM22 rearrangement. Am J Surg Pathol. 2012;36:1562–70.
42. Lee CH, Ou WB, Marino-Enriquez A, Zhu M, Mayeda M, Wang Y, et al. 14-3-3
fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl
Acad Sci U S A. 2012;109:929–34.
43. Ried T, Gaiser T. A recurrent fusion gene in high-grade endometrial stromal
sarcoma: a new tool for diagnosis and therapy? Genome Med. 2012;4:20.
44. Croce S, Hostein I, Ribeiro A, Garbay D, Velasco V, Stoeckle E, et al. YWHAE
rearrangement identified by FISH and RT-PCR in endometrial stromal sarcomas:
genetic and pathological correlations. Mod Pathol. 2013;26:1390–400.
45. Isphording A, Ali RH, Irving J, Goytain A, Nelnyk N, Hoang LN, et al. YWHAE-
FAM22 endometrial stromal sarcoma: diagnosis by reverse transcription-
polymerase chain reaction in formalin-fixed, paraffin-embedded tumor.
Human Pathol. 2013;44:837–43.
Hrzenjak Orphanet Journal of Rare Diseases  (2016) 11:15 Page 7 of 8
46. Sciallis PA, Bedroske PP, Schoolmeester JK, Sukov WR, Keeney GL, Hodge JC,
et al. High-grade endometrial stromal sarcomas: A clinicopathologic study
of a group of tumors with heterogeneous morphologic and genetic
features. Am J Surg Pathol. 2014;38:1161–72.
47. Lee CH, Nucci M. Endometrial stromal sarcoma - the new genetic paradigm.
Histopathology. 2015;67:1–19.
48. Lee CH, Marino-Enriquez A, Ou WB, Zhu M, Ali RH, Chiang S, et al. The
clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas:
a histologically high-grade and clinically aggressive tumor. Am J Surg
Pathol. 2012;36:641–53.
49. Dewaele B, Przybyl J, Quattrone A, Finalet Ferreiro J, Vanspauwen V,
Geerdens E, et al. Indentification of a novel, recurrent MBTD1-CXorf67 fusion
in low-grade endometrial stromal sarcoma. Int J Cancer. 2014;134:1112–22.
50. Panagopoulos I, Micci F, Thorsen J, Gorunova L, Eibak AM, Bjerkehagen B, et
al. Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial
stromal sarcoma. PLoS One. 2012;7:e39354.
51. Panagopoulos I, Thorsen J, Gorunova L, Haugom L, Bjerkehagen B, Davidson
B, et al. Fusion of the ZC3H7B and BCOR genes in endometrial stromal
sarcomas carrying an X;22-translocation. Genes Chromosomes Cancer. 2013;
52:610–8.
52. Micci F, Gorunova L, Gatius S, Matias-Guiu X, Davidson B, Heim S, et al.
MEAF6/PHF1 is a recurrent gene fusion in endometrial stromal sarcoma.
Cancer Lett. 2014;347:75–8.
53. Choi YJ, Jung SH, Kim MS, Baek IP, Rhee JK, Lee SH, et al. Genomic
landscape of endometrial stromal sarcoma of uterus. Oncotarget. 2015;6:
33319–28.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hrzenjak Orphanet Journal of Rare Diseases  (2016) 11:15 Page 8 of 8
